Phase I Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases

Trial Profile

Phase I Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Radium 223 chloride (Primary) ; Pazopanib; Sorafenib
  • Indications Bone metastases; Renal cell carcinoma
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 12 Sep 2017 Results assessing the safety, efficacy and bone turnover markers (BTM) of Radium-223 combined with Pazopanib or sorafenib in patients with metastatic renal cell carcinoma, presented at the 42nd European Society for Medical Oncology Congress.
    • 01 Aug 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top